Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BI 1744 CL in Healthy Male and Female Volunteers

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: BI 1744 CL; Drug: Placebo

• Registration Number: NCT02171806
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

To investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 1744 CL

Detailed Description

Not available

Study Timeline

• Study Start: 2006-01
• Primary Completion: 2006-09
• Status Verified: 2014-06
• Study First Submitted: 2014-06-20
• Study First Submitted QC: 2014-06-20
• Last Update Submitted: 2014-06-20
• Study First Posted: 2014-06-24
• Last Update Posted: 2014-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 47

Inclusion Criteria

• Healthy male or female based upon a complete medical history, including the physical examination, regarding vital signs (blood pressure (BP), pulse rate (PR)), 12-lead ECG measurement, and clinical laboratory tests. There is no finding deviating from normal and of clinical relevance. There is no evidence of a clinically relevant concomitant disease.
• Age ≥21 and ≤50 years
• BMI ≥18.5 and <30 kg/m2 (Body Mass Index)
• Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation

Read More

Exclusion Criteria

• Any finding of the medical examination (including BP, PR, and ECG measurements) deviating from normal and of clinical relevance
• Evidence of a clinically relevant concomitant disease
• Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
• Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
• History of relevant orthostatic hypotension, fainting spells or blackouts
• Chronic or relevant acute infections
• History of relevant allergy/hypersensitivity (including allergy to the drug or its excipients) as judged clinically relevant by the investigator
• Intake of drugs with a long half-life (>24 hours) within at least 1 month or less than 10 half-lives of the respective drug prior to randomisation
• Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to randomisation
• Participation in another trial with an investigational drug within 2 months prior to randomisation
• Smoker (>10 cigarettes or >3 cigars or >3 pipes/day)
• Inability to refrain from smoking on trial days as judged by the investigator
• Alcohol abuse (more than 60 g alcohol a day)
• Drug abuse
• Blood donation (more than 100 mL blood within 4 weeks prior to randomisation or during the trial)
• Excessive physical activities within 1 week prior to randomisation or during the trial
• Any laboratory value outside the reference range that is of clinical relevance
• Inability to comply with dietary regimen of the study centre

The following exclusion criteria are specific for this study due to the known class side effect profile of ß2-mimetics:

• Asthma or history of pulmonary hyperreactivity
• Hyperthyrosis
• Allergic rhinitis in need of treatment
• Clinically relevant cardiac arrhythmia
• Paroxysmal tachycardia (>100 beats per minute).

For female subjects:

• Pregnancy
• Positive pregnancy test
• No adequate contraception e.g. oral contraception, sterilisation, IUD (intrauterine device). Females who are not surgically sterile will be asked to additionally use barrier contraception methods (e.g. condoms) prior to administration of study medication, during the study and at least 2 months after release from the study.
• Inability to maintain this adequate contraception during the whole study period
• Lactation period

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
BI 1744 CL multiple rising doses	BI 1744 CL	-
Placebo	Placebo	-
BI 1744 CL medium dose, females	BI 1744 CL	-

Primary Outcome Measures

Name	Time	Method
Changes in tremormetry parameters	Baseline, up to day 32
Number of patients with clinically significant changes in physical examination	Baseline, day 32 (end-of-study examination)
Number of patients with clinically significant changes in vital signs	Baseline, up to day 32
Number of patients with clinically significant changes in 12-lead ECG (Electrocardiogram)	Baseline, up to day 32
Number of patients with abnormal changes in laboratory tests	Baseline, up to day 32
Changes in airway resistance (Raw) measured by body plethysmography	Baseline, up to day 32
Number of patients with adverse events	Up to day 32
Assessment of tolerability by the investigator on a 4-point scale	Day 32 (end-of-study examination)

Secondary Outcome Measures

Name	Time	Method
Cmax (maximum concentration of the analyte in plasma)	Up to 408 hours after drug administration
tmax (time from dosing to maximum concentration)	Up to 408 hours after drug administration
AUC (area under the concentration-time curve of the analyte in plasma at different time points)	Up to 408 hours after drug administration
Aet1-t2(amount of analyte that is eliminated in urine from the time point t1 to time point t2)	Up to 384 hours after drug administration
fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)	Up to 384 hours after drug administration
%AUCtz-∞ (the percentage of the AUC 0-∞ that is obtained by extrapolation)	Up to 408 hours after drug administration
λz (terminal rate constant of the analyte in plasma)	Up to 408 hours after drug administration
t½ (terminal half-life of the analyte in plasma)	Up to 408 hours after drug administration
MRTih (mean residence time of the analyte in the body after inhalation)	Up to 408 hours after drug administration
CL/F (apparent clearance of the analyte in the plasma after extravascular administration)	Up to 408 hours after drug administration
Vz/F (apparent volume of distribution of the analyte during the terminal phase λz following an extravascular dose)	Up to 408 hours after drug administration
CLR,t1-t2 (renal clearance of the analyte in plasma from the time point t1 until the time point t2)	Up to 408 hours after drug administration
RA,Cmax,14 based on Cmax (Accumulation ratio of the analyte in plasma after multiple dose administration over a uniform dosing interval τ)	Up to 408 hours after drug administration
RA,AUC,14 based on AUC0-τ	Up to 408 hours after drug administration
Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)	Up to 408 hours after drug administration
Cpre,ss (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose)	Up to 408 hours after drug administration
Linearity Index (LI)	Up to 408 hours after drug administration